الفهرس 
Optimization of the formulation of oral delivery system for improved bioavailability of an antiplatelet drug
List of contentsOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
Ticagrelor (TR) is an antiplatelet drug classified as a P2Y12 receptor antagonist. It is indicated for the prevention of thrombotic events as stroke or heart attack in patients with acute coronary syndrome(ACS) or myocardial infarction with ST-elevation. TR has one active metabolite, which has pharmacokinetics that is very similar to the parent compound.Therefore, TR has a more rapid onset and more pronounced platelet inhibition than other antiplatelet agents.TR is a class IV drug according to the biopharmaceutics classification system (BCS) with absolute bioavailability of 36% which is considered as an obstacle in oral drug delivery. It has poor solubility and permeability. Moreover, it is a substrate to P-glycoprotein (P-gp) which increases its efflux and decreases its systemic existence.This results in administrating frequent drug dosing (twice daily), that increases side effects, toxicity and decreases patient compliance.The objective of this study was to enhance the bioavailability of TR. The study is based on the preparation of oral lipid-based nanovesicles capable of increasing TR dissolution and permeability using two lipids, glyceryl monooleate (GMO) and sucrose acetate isobutyrate (SAIB) in a final tablet form as a comparative study